Stock Analysis on Net

Edwards Lifesciences Corp. (NYSE:EW)

This company has been moved to the archive! The financial data has not been updated since February 14, 2022.

Common Stock Valuation Ratios (Price Multiples)
Quarterly Data

Microsoft Excel

Historical Valuation Ratios (Summary)

Edwards Lifesciences Corp., historical price multiples (quarterly data)

Microsoft Excel
Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Price to earnings (P/E) 44.67 50.64 47.85 70.70 66.48 61.28 65.79 39.74 46.05 61.52 61.07 47.99 51.14 41.12 45.24 48.67 48.16
Price to operating profit (P/OP) 39.72 44.87 42.81 65.18 60.98 56.78 61.66 35.77 42.04 57.30 56.37 47.70 49.37 26.74 28.00 25.96 25.66
Price to sales (P/S) 12.83 14.68 14.21 13.45 12.48 11.14 11.32 9.82 11.09 11.46 11.17 9.61 9.92 8.06 8.37 7.91 8.18
Price to book value (P/BV) 11.50 13.50 13.63 12.91 11.97 11.56 12.74 11.29 11.62 12.48 12.65 10.65 11.76 8.72 9.39 8.40 9.51 6.82 8.30 8.39

Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. Edwards Lifesciences Corp. P/E ratio increased from Q2 2021 to Q3 2021 but then decreased significantly from Q3 2021 to Q4 2021.
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. Edwards Lifesciences Corp. P/OP ratio increased from Q2 2021 to Q3 2021 but then decreased significantly from Q3 2021 to Q4 2021.
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Edwards Lifesciences Corp. P/S ratio increased from Q2 2021 to Q3 2021 but then decreased significantly from Q3 2021 to Q4 2021.
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. Edwards Lifesciences Corp. P/BV ratio decreased from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021.

Price to Earnings (P/E)

Edwards Lifesciences Corp., historical P/E calculation (quarterly data)

Microsoft Excel
Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
No. shares of common stock outstanding1 623,207,437 624,334,496 623,327,843 621,636,777 624,518,873 623,248,273 621,740,581 619,664,253 627,367,734 625,710,042 623,907,657 625,504,809 623,298,987 627,147,807 628,157,934 632,337,345 630,071,124 634,859,673 633,474,090 629,408,397
Selected Financial Data (US$)
Net income (loss) (in thousands) 335,300 340,100 489,500 338,200 309,500 325,200 (121,900) 310,600 280,200 274,700 242,300 249,700 7,000 225,900 282,700 206,600 (2,800) 170,100 186,100 230,200
Earnings per share (EPS)2 2.41 2.37 2.35 1.37 1.32 1.27 1.20 1.79 1.67 1.24 1.16 1.22 1.16 1.14 1.05 0.89 0.93 0.00 0.00 0.00
Share price1, 3 107.73 119.82 112.27 96.78 87.65 78.08 78.69 71.05 76.85 76.07 70.95 58.71 59.26 46.71 47.29 43.10 44.61 33.97 38.50 36.56
Valuation Ratio
P/E ratio4 44.67 50.64 47.85 70.70 66.48 61.28 65.79 39.74 46.05 61.52 61.07 47.99 51.14 41.12 45.24 48.67 48.16
Benchmarks
P/E Ratio, Competitors5
Abbott Laboratories 29.13 31.42 33.80 36.79 48.49 58.45 58.36 45.61 41.83
Cigna Group 13.43 8.43 8.60 10.62 8.71 14.60 12.08 13.82 13.26
CVS Health Corp. 17.39 16.78 14.94 14.44 12.88 10.69 10.20 10.94 14.15
Elevance Health Inc. 18.13 18.65 22.10 19.99 15.87 14.35 11.97 14.80 15.96
Humana Inc. 18.34 22.09 22.82 15.20 14.48 13.49 15.26 19.09 18.10
Intuitive Surgical Inc. 59.94 71.86 69.15 89.95 87.47 82.17 70.73 44.27 48.72
Medtronic PLC 46.56 55.13 42.80 32.34 26.30 25.38 31.86 32.75 28.78
UnitedHealth Group Inc. 26.03 27.92 27.41 23.06 20.54 17.70 16.88 19.91 20.48

Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

1 Data adjusted for splits and stock dividends.

2 Q4 2021 Calculation
EPS = (Net income (loss)Q4 2021 + Net income (loss)Q3 2021 + Net income (loss)Q2 2021 + Net income (loss)Q1 2021) ÷ No. shares of common stock outstanding
= (335,300,000 + 340,100,000 + 489,500,000 + 338,200,000) ÷ 623,207,437 = 2.41

3 Closing price as at the filing date of Edwards Lifesciences Corp. Quarterly or Annual Report.

4 Q4 2021 Calculation
P/E ratio = Share price ÷ EPS
= 107.73 ÷ 2.41 = 44.67

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. Edwards Lifesciences Corp. P/E ratio increased from Q2 2021 to Q3 2021 but then decreased significantly from Q3 2021 to Q4 2021.

Price to Operating Profit (P/OP)

Edwards Lifesciences Corp., historical P/OP calculation (quarterly data)

Microsoft Excel
Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
No. shares of common stock outstanding1 623,207,437 624,334,496 623,327,843 621,636,777 624,518,873 623,248,273 621,740,581 619,664,253 627,367,734 625,710,042 623,907,657 625,504,809 623,298,987 627,147,807 628,157,934 632,337,345 630,071,124 634,859,673 633,474,090 629,408,397
Selected Financial Data (US$)
Operating income (loss) (in thousands) 374,400 390,300 542,100 383,500 351,400 357,800 (169,700) 358,100 310,800 294,300 267,500 274,200 (5,300) 248,900 252,100 252,500 342,200 214,000 241,000 298,300
Operating profit per share2 2.71 2.67 2.62 1.48 1.44 1.38 1.28 1.99 1.83 1.33 1.26 1.23 1.20 1.75 1.69 1.66 1.74 0.00 0.00 0.00
Share price1, 3 107.73 119.82 112.27 96.78 87.65 78.08 78.69 71.05 76.85 76.07 70.95 58.71 59.26 46.71 47.29 43.10 44.61 33.97 38.50 36.56
Valuation Ratio
P/OP ratio4 39.72 44.87 42.81 65.18 60.98 56.78 61.66 35.77 42.04 57.30 56.37 47.70 49.37 26.74 28.00 25.96 25.66
Benchmarks
P/OP Ratio, Competitors5
Abbott Laboratories 24.45 26.84 29.01 31.39 40.69 45.82 45.19 35.87 34.03
Cigna Group 9.08 9.12 9.28 11.13 9.03 9.24 7.58 8.59 8.38
CVS Health Corp. 10.43 9.43 7.87 7.61 6.65 5.89 5.98 6.19 7.83
Elevance Health Inc. 15.70 15.81 19.93 15.79 12.10 10.93 9.03 11.95 13.55
Humana Inc. 17.08 21.55 14.39 11.02 9.78 9.84 11.28 14.59 15.35
Intuitive Surgical Inc. 56.11 67.95 69.51 89.18 88.37 83.88 71.30 43.68 48.89
Medtronic PLC 37.44 49.88 42.55 35.86 26.29 21.01 23.52 22.21 21.26
UnitedHealth Group Inc. 18.77 19.63 19.05 16.12 14.12 12.35 11.85 13.80 14.40

Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

1 Data adjusted for splits and stock dividends.

2 Q4 2021 Calculation
Operating profit per share = (Operating income (loss)Q4 2021 + Operating income (loss)Q3 2021 + Operating income (loss)Q2 2021 + Operating income (loss)Q1 2021) ÷ No. shares of common stock outstanding
= (374,400,000 + 390,300,000 + 542,100,000 + 383,500,000) ÷ 623,207,437 = 2.71

3 Closing price as at the filing date of Edwards Lifesciences Corp. Quarterly or Annual Report.

4 Q4 2021 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 107.73 ÷ 2.71 = 39.72

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. Edwards Lifesciences Corp. P/OP ratio increased from Q2 2021 to Q3 2021 but then decreased significantly from Q3 2021 to Q4 2021.

Price to Sales (P/S)

Edwards Lifesciences Corp., historical P/S calculation (quarterly data)

Microsoft Excel
Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
No. shares of common stock outstanding1 623,207,437 624,334,496 623,327,843 621,636,777 624,518,873 623,248,273 621,740,581 619,664,253 627,367,734 625,710,042 623,907,657 625,504,809 623,298,987 627,147,807 628,157,934 632,337,345 630,071,124 634,859,673 633,474,090 629,408,397
Selected Financial Data (US$)
Net sales (in thousands) 1,329,700 1,310,200 1,376,000 1,216,600 1,191,700 1,140,900 925,000 1,128,700 1,174,100 1,094,000 1,086,900 993,000 977,700 906,600 943,700 894,800 888,500 821,500 841,800 883,500
Sales per share2 8.40 8.16 7.90 7.20 7.02 7.01 6.95 7.24 6.93 6.64 6.35 6.11 5.97 5.79 5.65 5.45 5.45 0.00 0.00 0.00
Share price1, 3 107.73 119.82 112.27 96.78 87.65 78.08 78.69 71.05 76.85 76.07 70.95 58.71 59.26 46.71 47.29 43.10 44.61 33.97 38.50 36.56
Valuation Ratio
P/S ratio4 12.83 14.68 14.21 13.45 12.48 11.14 11.32 9.82 11.09 11.46 11.17 9.61 9.92 8.06 8.37 7.91 8.18
Benchmarks
P/S Ratio, Competitors5
Abbott Laboratories 4.78 5.38 5.36 5.64 6.30 6.13 5.77 5.09 4.83
Cigna Group 0.42 0.42 0.42 0.55 0.46 0.50 0.41 0.45 0.44
CVS Health Corp. 0.47 0.45 0.39 0.40 0.35 0.32 0.32 0.30 0.37
Elevance Health Inc. 0.81 0.78 0.73 0.76 0.60 0.61 0.63 0.65 0.74
Humana Inc. 0.65 0.73 0.71 0.73 0.64 0.76 0.76 0.74 0.76
Intuitive Surgical Inc. 17.89 22.12 21.73 23.19 21.29 20.09 18.44 13.33 15.01
Medtronic PLC 5.57 5.71 5.43 5.11 4.36 4.34 4.82 4.72 4.36
UnitedHealth Group Inc. 1.58 1.55 1.47 1.49 1.24 1.18 1.17 1.12 1.18

Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

1 Data adjusted for splits and stock dividends.

2 Q4 2021 Calculation
Sales per share = (Net salesQ4 2021 + Net salesQ3 2021 + Net salesQ2 2021 + Net salesQ1 2021) ÷ No. shares of common stock outstanding
= (1,329,700,000 + 1,310,200,000 + 1,376,000,000 + 1,216,600,000) ÷ 623,207,437 = 8.40

3 Closing price as at the filing date of Edwards Lifesciences Corp. Quarterly or Annual Report.

4 Q4 2021 Calculation
P/S ratio = Share price ÷ Sales per share
= 107.73 ÷ 8.40 = 12.83

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Edwards Lifesciences Corp. P/S ratio increased from Q2 2021 to Q3 2021 but then decreased significantly from Q3 2021 to Q4 2021.

Price to Book Value (P/BV)

Edwards Lifesciences Corp., historical P/BV calculation (quarterly data)

Microsoft Excel
Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
No. shares of common stock outstanding1 623,207,437 624,334,496 623,327,843 621,636,777 624,518,873 623,248,273 621,740,581 619,664,253 627,367,734 625,710,042 623,907,657 625,504,809 623,298,987 627,147,807 628,157,934 632,337,345 630,071,124 634,859,673 633,474,090 629,408,397
Selected Financial Data (US$)
Stockholders’ equity (in thousands) 5,835,900 5,541,300 5,133,300 4,658,400 4,574,300 4,210,300 3,839,100 3,901,100 4,148,300 3,814,800 3,500,300 3,447,500 3,140,400 3,361,300 3,164,200 3,245,700 2,956,200 3,162,500 2,939,600 2,742,700
Book value per share (BVPS)2 9.36 8.88 8.24 7.49 7.32 6.76 6.17 6.30 6.61 6.10 5.61 5.51 5.04 5.36 5.04 5.13 4.69 4.98 4.64 4.36
Share price1, 3 107.73 119.82 112.27 96.78 87.65 78.08 78.69 71.05 76.85 76.07 70.95 58.71 59.26 46.71 47.29 43.10 44.61 33.97 38.50 36.56
Valuation Ratio
P/BV ratio4 11.50 13.50 13.63 12.91 11.97 11.56 12.74 11.29 11.62 12.48 12.65 10.65 11.76 8.72 9.39 8.40 9.51 6.82 8.30 8.39
Benchmarks
P/BV Ratio, Competitors5
Abbott Laboratories 5.75 6.61 6.38 6.27 6.65 6.30 5.94 5.40 4.96 4.65 4.86 4.49
Cigna Group 1.53 1.49 1.44 1.86 1.46 1.61 1.34 1.51 1.49 1.49 1.44 1.42
CVS Health Corp. 1.83 1.71 1.47 1.51 1.33 1.24 1.24 1.21 1.47 1.47 1.23 1.25
Elevance Health Inc. 3.07 2.88 2.67 2.78 2.19 2.10 2.06 2.23 2.42 2.13 2.40 2.15
Humana Inc. 3.34 3.63 3.82 3.99 3.55 3.55 3.71 4.04 4.07 3.48 3.38 3.07
Intuitive Surgical Inc. 8.59 10.64 10.35 10.40 9.53 9.35 9.19 7.22 8.13 8.43 8.49 8.68
Medtronic PLC 3.26 3.14 3.02 2.84 2.48 2.60 2.94 2.87 2.66 2.48 2.62 2.59
UnitedHealth Group Inc. 6.27 6.13 5.76 5.86 4.83 4.54 4.53 4.81 4.92 4.32 4.40 4.37

Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

1 Data adjusted for splits and stock dividends.

2 Q4 2021 Calculation
BVPS = Stockholders’ equity ÷ No. shares of common stock outstanding
= 5,835,900,000 ÷ 623,207,437 = 9.36

3 Closing price as at the filing date of Edwards Lifesciences Corp. Quarterly or Annual Report.

4 Q4 2021 Calculation
P/BV ratio = Share price ÷ BVPS
= 107.73 ÷ 9.36 = 11.50

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. Edwards Lifesciences Corp. P/BV ratio decreased from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021.